Kaufman and Verheyden, any statements relating to product efficacy, clinical trials or studies, potential treatments or indications, therapeutic outcomes or treatment responses, and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Learn more at Cautionary Note Regarding Forward-Looking StatementsĬertain information in this press release may be considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and any applicable Canadian securities legislation including, but not limited to, the statements by Drs. With provider relationships for patient access, Pulse Infoframe ensures that insights, evidence, and publication results are disseminated across the ecosystem, including advocacy organizations, key opinion leaders, researchers, and sponsors. Pulse Infoframe provides a full solution for registries, natural history studies, and other observational and regulatory grade studies. Pulse Infoframe is a real-world evidence generation, health informatics, and insights company that has built a structured technology and services platform designed to extract, curate, analyze, and disseminate evidence-based conclusions that improve the quality of people's lives. Learn more at or connect with us on LinkedIn. Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Our decades of proven success come from passionate team members around the globe collaborating to bring treatments forward. As DC progresses, it may become difficult for individuals to use their hand(s) for daily tasks and activities.Įndo (OTC: ENDPQ) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. It's caused by a buildup of collagen in the hand, which forms a rope-like cord that pulls fingers toward the palm so they can't be straightened. Healthcare providers will answer questions related to, but not limited to, the reason for treatment choice details of contracture size, location and number of cords treated active and passive range of motion before and after treatment and treatment techniques used.ĭC is a lifelong condition that may get worse over time. Patients will answer questions related to, but not limited to, quality of life, reasons for treatment choices, functional outcomes, activities before and after treatment, treatment satisfaction and self-reported treatment effectiveness. Patients will be followed for up to three years, and data will be collected from both the patients and their healthcare providers. GRASP-DC (NCT05877066) is a non-interventional study of up to 1,000 DC patients from 15 sites who have initiated treatment within two weeks before, at or any time after the date of enrollment. Philip Blazar, Gary Pess and James Verheyden. The Study is run by a steering committee that consists of Endo, Pulse Infoframe and Drs. "This study will result in the creation of a single registry to facilitate more comprehensive knowledge of treatment and management using real-world evidence." "Due to the low diagnosis rate and typically slow progression of Dupuytren's contracture, the currently available data on the condition is insufficient," said James Verheyden, M.D., a hand and upper extremity surgeon who enrolled the first patient. "Along with our study steering committee partners, Endo is committed to supporting the Dupuytren's patient community." "We're pleased to support this unprecedented effort to help advance understanding and treatment of Dupuytren's contracture," said Gregory Kaufman, M.D., Vice President, Medical Affairs and Chief Medical Officer at Endo. This registry will create the largest and most comprehensive collection of real-world DC data on treatment outcomes.ĭC is a progressive hand condition that results in the formation of a collagen rope-like cord that pulls fingers toward the palm and affects an estimated 14 million Americans. DUBLIN, J/PRNewswire/ - Endo International plc (OTC: ENDPQ) announced today that the first patient has been enrolled in GRASP-DC (Generating Real-world Ambispective data to Study Participant Treatment outcomes for Dupuytren's Contracture), a non-interventional registry of up to 1,000 patients with Dupuytren's contracture (DC).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |